SCHEMBL3872023

SCHEMBL3872023

Oc1nc2cccc(O)c2c2[nH]cnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.40
ABL1 P00519 1/20 0.38
RAD52 P43351 1/20 0.38
RIN1 Q13671 1/20 0.38
GAA P10253 3/20 0.37
MAPT P10636 2/20 0.37
ALDH1A1 P00352 2/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PNP P00491 1/20 0.34
MMP2 P08253 1/20 0.33
CHRM1 P11229 1/20 0.33
TSHR P16473 1/20 0.33
COMT P21964 1/20 0.33
ADRA1A P35348 1/20 0.33
METAP2 P50579 1/20 0.33
METAP1 P53582 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
BRAF P15056 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL311169 0.77 JAK2 (0.41) ABL1RAD52RIN1GAAMAPT
Hydrochloric Acid SCHEMBL9037659 0.75 JAK2 (0.41) ABL1RAD52RIN1GAAMAPT
SCHEMBL311313 0.75 MMP2 (0.38) ACHEMAPTALDH1A1KMT2AMMP2
SCHEMBL1019602 0.71 QPCT (0.42) ACHEGAAMAPTALDH1A1RAB9A
SCHEMBL1520970 0.70 QPCT (0.40) ACHEGAAMAPTALDH1A1RAB9A
Bromide SCHEMBL14831945 0.70 QPCT (0.41) ACHEGAAMAPTALDH1A1RAB9A
SCHEMBL482752 0.67 ACHE (0.46) ACHEGAAMAPTALDH1A1RAB9A
SCHEMBL4032577 0.66 PARP1 (0.64) ABL1MAPTALDH1A1RAB9APNP
SCHEMBL8571306 0.66 PARP1 (0.46) ACHEABL1RAD52RIN1PARP1
SCHEMBL10971610 0.66 PARP1 (0.46) ABL1RAD52RIN1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598382-B2 Aryl substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-10-06 US disclosed
US-7091214-B2 Aryl substituted Imidazoquinolines 3M INNOVATIVE PROPERTIES CO. (US) 2006-08-15 US disclosed
US-20060111387-A1 ARYL SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY 2006-05-25 US disclosed
EP-1590348-A1 ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2005-11-02 EP disclosed
US-20040147543-A1 Aryl substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-07-29 US disclosed
WO-2004058759-A1 ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147543-A1 Aryl substituted imidazoquinolines IL2, IFNG, IRF3 ACHE 4494/4885ABL1 137/4885RAD52 1827/4885
US-20060111387-A1 ARYL SUBSTITUTED IMIDAZOQUINOLINES IL2, IFNG, IRF3 ACHE 4494/4885ABL1 137/4885RAD52 1827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.